Vogt-Koyanagi-Harada disease

Nenhuma Miniatura disponível
Citações na Scopus
0
Tipo de produção
bookPart
Data de publicação
2011
Scopus
Título da Revista
ISSN da Revista
Título do Volume
Editora
NOVA SCIENCE PUBLISHERS, INC.
Autores
SOUZA, A. W. de
APPENZELLER, S.
Citação
de Carvalho, J. F.; de Souza, A. W.; Yamamoto, J. H.; Appenzeller, S.. Vogt-Koyanagi-Harada disease. In: . Advances in Eye Research, v.1: NOVA SCIENCE PUBLISHERS, INC., 2011. p.147-158.
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
The term panuveitis is reserved for diseases that involve all segments of the uveal tract, including the retina and vitreous body. It is usually associated with severe sight-threatening inflammatory response. The common causes of panuveitis in our population are tuberculosis, syphilis, Vogt-Koyanagi-Harada disease, sympathetic ophthalmia, Behçet’s disease and sarcoidosis. Vogt-Koyanagi-Harada disease (VKH) is a multisystem autoimmune disorder affecting pigmented tissues such as the eye, auditory, integumentary and central nervous systems. Patients are typically females between 20 to 50 years old with no previous history of penetrating ocular trauma. Despite the increasing reports published about the clinical features of VKHdisease in various ethnic populations, the etiology of VKH disease is still not completely known. Clinical, laboratorial, experimental data corroborate to the autoimmune nature of VKH disease in a genetically susceptible individual. A stepwise approach is essential while evaluating these patients to be able to identify and treat the disease timely and adequately. Ancillary tests can be appropriately applied once the clinical diagnosis is made. Treatment is based on initial high-dose oral corticosteroids with a low tapering during a minimum period of 6 months. Systemic immunomodulatory agents such as cyclosporine may be used in refractory or corticosteroid non-tolerant patients. Visual prognosis is usually good under a prompt diagnosis and adequate treatment. The aim of this paper is to review the latest research results on VKH disease in order to help to understand better this potentially blinding disease and to improve treatment. © 2011 Nova Science Publishers, Inc.
Palavras-chave
Diagnostic criteria, Uveitis, Vogt-koyanagi-harada
URI
https://observatorio.fm.usp.br/handle/OPI/57263
Referências
  1. Koyanagi Y.D., Alopecia und poliosis bei schwerer Uveitis nicht traumatischen Ursprungs, Klin Monatsbl Augenkeikd, 194, pp. 194-211, (1929)
  2. Vogt A., Fruhzeitiges Ergaruen der Zilien und Bemerkungen uber den sogenaten plotzlichen Eintreitt dieser Veranderung, Klin Monatsbl Augenkeikd, 44, pp. 228-242, (1906)
  3. Harada E., Acute diffuse choroiditis, Acta Soc Ophtalmol Jpn, 30, pp. 356-378, (1926)
  4. Read R.W., Holland G.N., Rao N.A., Et al., Revised diagnostic criteria for Vogt-Koyanagi-Harada disease: Report of an international committee on nomenclature, Am J Ophtalmol, 131, pp. 647-652, (2001)
  5. Snyder D.A., Tessler H.H., Vogt-Koyanagi-Harada syndrome, Am J ophthalmol, 90, pp. 69-75, (1980)
  6. Belfort Junior R., Nishi M., Hayashi S., Et al., Vogt-Koyanagi-Harada’s disease in Brazil, Jpn J Ophthalmol, 32, pp. 344-347, (1988)
  7. Moorthy R.S., Inomata J., Rao N.A., Vogt-Koyanagi-Harada syndrome, Surv Ophthalmol, 39, pp. 265-292, (1995)
  8. Damico F.M., Cunha-Neto E., Goldberg A.C., Et al., T-cell recognition and cytokine profile induced by melanocyte epitopes inpatients with HLADRB1* 0405-positive and -negative Vogt-Koyanagi-Harada uveitis, Invest Ophthalmol Vis Sci., 46, pp. 2465-2471, (2005)
  9. Yamaki K., Gocho K., Hayakawa K., Et al., Tyrosinase family proteins are antigens specific to Vogt-Koyanagi-Harada disease, J Immunol, 165, pp. 7323-7329, (2000)
  10. Shindo Y., Ohno S., Yamamoto T., Nakamura S., Inoko H., Complete association of the HLA-DRB1*04 and -DQB1*04 alleles with Vogt-Koyanagi-Harada’s disease, Hum Immunol, 39, pp. 169-176, (1994)
  11. Goldberg A.C., Yamamoto J.H., Chiarella J.M., Et al., HLA-DRB1*0405 is the predominant allele in Brazilian patients with Vogt-Koyanagi-Harada disease, Hum Immunol, 59, pp. 183-188, (1998)
  12. de Smet M.D., Yamamoto J.H., Mochizuki M., Gery I., Singh V.K., Shinohara T., Wiggert B., Chader G.J., Nussenblatt R.B., Cellular immune responses of patients with uveitis to retinal antigens and their fragments, Am J Ophthalmol, 110, 2, pp. 135-142, (1990)
  13. Chee S.-P., Chi D.L., Cheng C.L., Et al., Visual function in Vogt-Konayagi-Harada patients, Graefe’s Arch Clin Exp Ophthalmol, 243, pp. 785-790, (2005)
  14. da Silva F.T., Damico F.M., Marin M.L., Goldberg A.C., Hirata C.E., Takiuti P.H., Olivalves E., Yamamoto J.H., Revised diagnostic criteria for Vogt Koyanagi-Harada disease: Considerations on the different disease categories, Am J Ophthalmol, 147, 2, pp. 339-345, (2009)
  15. Shinzato M., Yamamoto J.H., Hirata C.E., Et al., Anti-SS-A/Ro reactivity in patients with Vogt-Koyanagi-Harada syndrome, Lupus, 13, pp. 279-280, (2004)
  16. Yamamoto J.H., Damico F.M., Hirata C.E., Kubo P.Y., Goldberg A.C., Kalil J., Olivalves E., Epidemiological and clinical features of Brazilian patients with VKH syndrome, Proceedings of the Vth International Symposium on Uveitis., (2000)
  17. Paredes I., Ahmed M., Foster C.S., Immunomodulatory therapy for VKH patients as first line therapy, Ocul Immunol Inflamm., 14, pp. 87-90, (2006)
  18. Jabs D.A., Rosenbaum J.T., Foster C.S., Et al., Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: Recommendations of an expert panel, Am J Ophthalmol., 130, pp. 492-513, (2000)
  19. Nussenblatt R.B., Fortin E., Schiffman R., Et al., Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: A phase I/II clinical trial, Proc Natl Acad Sci USA., 96, pp. 7462-7466, (1999)

Coleções
Livros e Capítulos de Livros - HC/ICHC
Livros e Capítulos de Livros - LIM/17
Livros e Capítulos de Livros - LIM/33